 The study found that dupilumab treatment of adults with moderate to severe atopic dermatitis up to three years did not show any clinically meaningful changes in mean laboratory parameters and no eosinophil abnormalities were associated with clinically symptomatic events permanent treatment discontinuation. The study supports the continuous long-term use of dupilumab without routine laboratory monitoring. This article was offered by Lisa A. Beck, Diamond Fosse, Metadeleuron, and others.